Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - gefitinib - tablet, film coated - 250 mg - gefitinib 250 mg

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole - injection, powder, for solution - 40 mg - esomeprazole 40 mg

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide; formoterol fumarate dihydrate - powder, metered - 160 mcg/dose - budesonide 160 mcg/dose; formoterol fumarate dihydrate 4.5 mcg/dose

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide; formoterol fumarate dihydrate - powder, metered - 80 mcg/dose - budesonide 80 mcg/dose; formoterol fumarate dihydrate 4.5 mcg/dose

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - tamoxifen citrate 15.2 mg eqv tamoxifen - tablet, film coated - 10 mg - tamoxifen citrate 15.2 mg eqv tamoxifen 10 mg

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - tamoxifen citrate 30.4mg eqv tamoxifen - tablet, film coated - 20 mg - tamoxifen citrate 30.4mg eqv tamoxifen 20 mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; water for injections; citric acid; sodium citrate dihydrate; sodium hydroxide - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.